Literature DB >> 8113035

Surfactant therapy in respiratory distress syndrome: the effect of a learning curve in improving outcome.

S M Gormally1, T A Clarke, A Krishnan, M Ali, T G Matthews.   

Abstract

A retrospective study of all premature neonates who received artificial surfactant (Curosurf) at the Rotunda Hospital was performed. The period from October 1990 to June 1992 (n = 48) was compared with the initial experience from June 1987 to January 1988 (n = 15). In the initial period mortality rate was 67% in surfactant treated infants, and use of surfactant was not associated with an improvement in outcome compared with the previous six years. In the more recent period overall mortality was 21%. Overall survival in normally formed very low birthweight infants improved from 59% in 1986 to 86% in 1991-1992. Improvement in survival rates was most noticeable in infants with birthweight 750-999 grams, with survival increasing from 44% (before introduction of surfactant treatment) to 91% (in 1991-1992). It is probable that a certain level of experience with use of surfactant is required before optimal effects can be obtained.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8113035     DOI: 10.1007/bf02942189

Source DB:  PubMed          Journal:  Ir J Med Sci        ISSN: 0021-1265            Impact factor:   1.568


  15 in total

1.  Randomized European multicenter trial of surfactant replacement therapy for severe neonatal respiratory distress syndrome: single versus multiple doses of Curosurf.

Authors:  C P Speer; B Robertson; T Curstedt; H L Halliday; D Compagnone; O Gefeller; K Harms; E Herting; G McClure; M Reid
Journal:  Pediatrics       Date:  1992-01       Impact factor: 7.124

2.  Cerebral blood flow velocity changes after rapid administration of surfactant.

Authors:  F Cowan; A Whitelaw; D Wertheim; M Silverman
Journal:  Arch Dis Child       Date:  1991-10       Impact factor: 3.791

3.  Surfactant replacement therapy for severe neonatal respiratory distress syndrome: an international randomized clinical trial. Collaborative European Multicenter Study Group.

Authors: 
Journal:  Pediatrics       Date:  1988-11       Impact factor: 7.124

Review 4.  Respiratory distress syndrome and intracranial hemorrhage: cause or association? Inferences from surfactant clinical trials.

Authors:  A Leviton; L VanMarter; K C Kuban
Journal:  Pediatrics       Date:  1989-11       Impact factor: 7.124

5.  Surfactant treatment and incidence of intraventricular haemorrhage in severe respiratory distress syndrome.

Authors:  F B McCord; T Curstedt; H L Halliday; G McClure; M M Reid; B Robertson
Journal:  Arch Dis Child       Date:  1988-01       Impact factor: 3.791

6.  A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants.

Authors:  G C Liggins; R N Howie
Journal:  Pediatrics       Date:  1972-10       Impact factor: 7.124

7.  A comparison of surfactant as immediate prophylaxis and as rescue therapy in newborns of less than 30 weeks' gestation.

Authors:  J W Kendig; R H Notter; C Cox; L J Reubens; J M Davis; W M Maniscalco; R A Sinkin; A Bartoletti; H S Dweck; M J Horgan
Journal:  N Engl J Med       Date:  1991-03-28       Impact factor: 91.245

8.  A European multicenter randomized controlled trial of single dose surfactant therapy for idiopathic respiratory distress syndrome.

Authors:  J D Horbar; R F Soll; H Schachinger; G Kewitz; H T Versmold; W Lindner; G Duc; D Mieth; O Linderkamp; E P Zilow
Journal:  Eur J Pediatr       Date:  1990-03       Impact factor: 3.183

9.  Epidemiology and classification of acute, neonatal respiratory disorders. A prospective study.

Authors:  O Hjalmarson
Journal:  Acta Paediatr Scand       Date:  1981-11

10.  Effect of antenatal dexamethasone administration on the prevention of respiratory distress syndrome.

Authors: 
Journal:  Am J Obstet Gynecol       Date:  1981-10-01       Impact factor: 8.661

View more
  1 in total

1.  A risk-benefit assessment of natural and synthetic exogenous surfactants in the management of neonatal respiratory distress syndrome.

Authors:  H Walti; M Monset-Couchard
Journal:  Drug Saf       Date:  1998-05       Impact factor: 5.606

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.